RIGL - Rigel Pharmaceuticals Inc.

RIGL Stock Chart

RIGL Profile

Rigel Pharmaceuticals, Inc., a prominent biotechnology firm, specializes in the discovery, development, and provision of small molecule drugs aimed at improving the quality of life for patients battling hematologic disorders, cancer, and rare immune diseases. The company's innovative pipeline includes commercialized products such as Tavalisse, an oral spleen tyrosine kinase inhibitor prescribed for adult patients suffering from chronic immune thrombocytopenia. Additionally, Rigel Pharmaceuticals offers Rezlidhia, a non-intensive monotherapy designed for adult patients with relapsed or refractory acute myeloid leukemia (AML) featuring a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as identified by an FDA-approved test.

The company is actively advancing Fostamatinib, a promising drug that has completed phase III clinical trials for treating warm autoimmune hemolytic anemia and has shown potential in managing COVID-19. Notably, Fostamatinib has concluded the FOCUS phase III clinical trial targeting hospitalized high-risk COVID-19 patients and is undergoing phase III trials for COVID-19 treatment in hospitalized settings. Rigel Pharmaceuticals also collaborates on clinical programs including interleukin receptor-associated kinase inhibitor and receptor-interacting serine/threonine-protein kinase inhibitor initiatives with Eli Lilly and Company.

In addition to its robust pipeline, Rigel Pharmaceuticals partners with leading biopharmaceutical companies like BerGenBio ASA and Daiichi Sankyo to develop promising product candidates. These collaborations further underscore the company's commitment to expanding its therapeutic offerings and advancing medical treatments across various disease areas.

Founded in 1996 and headquartered in South San Francisco, California, Rigel Pharmaceuticals continues to drive innovation in biotechnology with a dedicated focus on addressing unmet medical needs. The company's strategic partnerships and diverse portfolio of clinical programs reinforce its position as a key player in the biopharmaceutical industry, poised to make significant contributions to patient care and medical advancements globaly.

RIGL Revenue Chart

RIGL Earnings

Analyst Ratings